

Placental vascular pathology and increased thrombin generation as mechanisms of disease in obstetrical syndromes

Salvatore Andrea Mastrolia^{1,2}, Moshe Mazor², Giuseppe Loverro¹, Vered Klaitman² and Offer Erez²

¹ Department of Obstetrics and Gynecology, Azienda Ospedaliera-Universitaria Policlinico di Bari, School of Medicine, University of Bari "Aldo Moro", Bari, Italy

² Department of Obstetrics and Gynecology, Soroka University Medical Center, School of Medicine, Ben Gurion University of the Negev, Beer Sheva, Israel

ABSTRACT

Obstetrical complications including preeclampsia, fetal growth restriction, preterm labor, preterm prelabor rupture of membranes and fetal demise are all the clinical endpoint of several underlying mechanisms (i.e., infection, inflammation, thrombosis, endocrine disorder, immunologic rejection, genetic, and environmental), therefore, they may be regarded as syndromes. Placental vascular pathology and increased thrombin generation were reported in all of these obstetrical syndromes. Moreover, elevated concentrations of thrombin-anti thrombin III complexes and changes in the coagulation as well as anticoagulation factors can be detected in the maternal circulation prior to the clinical development of the disease in some of these syndromes. In this review, we will assess the changes in the hemostatic system during normal and complicated pregnancy in maternal blood, maternal–fetal interface and amniotic fluid, and describe the contribution of thrombosis and vascular pathology to the development of the great obstetrical syndromes.

Subjects Gynecology and Obstetrics, Hematology

Keywords Coagulation, TAT III complexes, TFPI, Protein Z, Amniotic fluid, IUGR, PROM, Preeclampsia, Fetal demise, Preterm labor

Submitted 3 September 2014
Accepted 14 October 2014
Published 18 November 2014

Corresponding author
Offer Erez, erezof@bgu.ac.il

Academic editor
Hendrik Feys
Additional Information and
Declarations can be found on
page 17

DOI 10.7717/peerj.653

© Copyright
2014 Mastrolia et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

INTRODUCTION

Obstetrical complications including preeclampsia, fetal growth restriction, preterm labor, preterm prelabor rupture of membranes and fetal demise are all the clinical endpoint of several underlying mechanisms (i.e., infection, inflammation, thrombosis, endocrine disorder, immunologic rejection, genetic, and environmental), therefore, they may be regarded as syndromes. In this review, we will assess the changes in the hemostatic system during normal and complicated pregnancy in maternal blood, maternal–fetal interface and amniotic fluid, and describe the contribution of thrombosis and vascular pathology to the development of the great obstetrical syndromes.

WHAT ARE THE GREAT OBSTETRICAL SYNDROMES?

The major obstetrical complications including preeclampsia, intrauterine growth restriction (IUGR), preterm labor (PTL), preterm prelabor rupture of membranes

(PROM), fetal demise, and recurrent abortions are all syndromes, also defined as “great obstetrical syndromes”. As reported in The Oxford Medical Dictionary a syndrome is ‘a combination of symptoms and/or signs that form a distinct clinical picture indicative of a particular disorder’. Hence, they represent the clinical manifestation of many possible underlying mechanisms of disease (*Concise Medical Dictionary, 2010*).

Key features of these syndromes are (*Romero, 2009*): multiple etiologies; long preclinical stage; frequent fetal involvement; clinical manifestations which are often adaptive in nature; and predisposition to a particular syndrome is influenced by gene–environment interaction and/or complex gene–gene interactions involving maternal and/or fetal genotypes. These mechanisms of disease were identified and reported in all the obstetrical complications listed above. This review is focused on the role of thrombosis and vascular pathology of the placenta in these syndromes.

WHAT ARE THE CHANGES IN THE COAGULATION SYSTEM DURING NORMAL PREGNANCY?

In term of the coagulation and hemostatic systems there are several major compartments: the maternal circulation, the fetal maternal interface (the placenta, and the membranes), the amniotic fluid and the fetus and each has a specific behavior during gestation. The changes in the coagulation system during gestation are considered to be adaptive mechanisms and are aimed to: (1) the prevention of bleeding at the time of trophoblast implantation and the delivery of the fetus; (2) allow the laminar flow at the intervillous space; and (3) seal amniotic fluid leak and reduce obstetrical bleeding (*Bellart et al., 1998; Walker et al., 1997; Sørensen, Secher & Jespersen, 1995; Yuen, Yin & Lao, 1989; de Boer et al., 1989*). Of interest, the fetus is somewhat less involved and its coagulation system develops during gestation, and this subject is beyond the scope of this review.

Indeed, normal pregnancy has been associated with excessive maternal thrombin generation (*Bellart et al., 1998; Chaiworapongsa et al., 2002*) and a tendency for platelets to aggregate in response to agonists (*Yoneyama et al., 2000; Sheu et al., 2002*). Pregnancy is accompanied by 2 to 3-fold increase in fibrinogen concentrations and 20% to 1000% increase in factors VII, VIII, IX, X, and XII, all of which peak at term (*Bremme, 2003*). The concentration of vWF increase up to 400% by term (*Bremme, 2003*). By contrast, those of pro-thrombin and factor V remain unchanged while the concentrations of factors XIII and XI decline modestly (*Eichinger et al., 1999*). Indeed there is evidence of chronic low-level thrombin and fibrin generation throughout normal pregnancy as indicated by enhanced concentrations of pro-thrombin fragment 1 and 2, thrombin–antithrombin (TAT) III complexes, and soluble fibrin polymers (*Ku et al., 2003*). Free protein S concentration declines significantly (up to 55%) during pregnancy due to increased circulating complement 4B-binding protein, its molecular carrier. Protein S nadir at delivery and this reduction is exacerbated by cesarean delivery and infection (*Bremme, 2003; Eichinger et al., 1999*). As a consequence, pregnancy is associated with an increase in resistance to activated protein C (*Eichinger et al., 1999; Ku et al., 2003*). The concentration of PAI-1 increase by 3 to 4-fold during pregnancy while plasma PAI-2 values, which are negligible before pregnancy, reach

concentrations of 160 mg/L at delivery (*Bremme, 2003*). Thus, pregnancy is associated with increased clotting potential, as well as decreased anticoagulant properties, and fibrinolysis (*Lockwood, 2006*). Therefore, it can be defined as a prothrombotic state. One of the most important mediators of the hypercoagulable state of normal pregnancy is tissue factor (TF). Indeed, there is a substantial increase in TF concentrations in the decidua and myometrium (*Erlich et al., 1999; Kuczyński et al., 2002; Lockwood, Krikun & Schatz, 2001; Lockwood, Krikun & Schatz, 1999*), preventing placental abruption since this leads to an increase in the efficiency of clotting function (*Lockwood, 2006*). The placenta is a source of TF, since trophoblast cells constitutively express it, behaving as activated endothelium, and leading to a condition of procoagulant state that, if not controlled by anticoagulant mechanisms, predisposes to thrombotic complications (*Erlich et al., 1999*). The principal anticoagulant mechanism inhibiting TF activation pathway is tissue factor pathway inhibitor (TFPI), which mRNA is highly expressed in the macrophages in the villi in term placenta (*Edstrom, Calhoun & Christensen, 2000*).

Similarly, high TF concentrations have been detected in the fetal membranes (mainly the amnion) and amniotic fluid (*de Boer et al., 1989; Uszyński et al., 2001; Lockwood et al., 1991; Omsjøl et al., 1985; Creter, 1977*). TFPI has been found in amniotic fluid as well (*Uszyński et al., 2001*), but it is not clear if the presence of TF and its natural inhibitor is related to coagulation per se or is somehow connected with embryonic development (*Carmeliet et al., 1996*).

In contrast to the changes detected in the amniotic fluid and the decidua, the median maternal plasma immunoreactive TF concentration of normal pregnant women do not differ significantly from that of non-pregnant patients (*Bellart et al., 1998; Holmes & Wallace, 2005*). However, labor at term increases significantly the maternal plasma immunoreactive TF concentration in comparison to the non-pregnant state (*Uszyński et al., 2001*). In addition to the changes in TF, normal pregnancy is associated with increased thrombin generation (*Bellart et al., 1998; Chaiworapongsa et al., 2002*), as determined by the elevation of maternal concentrations of fibrinopeptide A, prothrombin fragments (PF) 1 and 2, and thrombin–antithrombin (TAT) III complexes (*de Boer et al., 1989; Reber, Amiral & de Moerloose, 1998; Uszyński, 1997; Reinthaller, Mursch-Edlmayr & Tatra, 1990*). The concentration of these complexes further increases during and after normal parturition (*Uszyński, 1997; Andersson et al., 1996*), and subsequently decreases during the puerperium (*Uszyński, 1997; Andersson et al., 1996*).

WHAT ARE THE CHANGES IN THE HEMOSTATIC SYSTEM ASSOCIATED WITH THE GREAT OBSTETRICAL SYNDROMES?

The great obstetrical syndromes are associated with changes in the hemostatic and vascular systems in the compartments mentioned above: (1) the maternal circulation; (2) the feto-maternal interface of placenta and membranes; (3) and the amniotic fluid.

Changes in the hemostatic system of women with obstetrical syndromes

The involvement of the hemostatic system in the pathophysiology of these obstetrical syndromes is becoming more and more apparent. Indeed, increased thrombin generation is reported in the maternal circulation of women with preeclampsia (*Schjetlein et al., 1999; Chaiworapongsa et al., 2002; Hayashi et al., 1998; Kobayashi & Terao, 1987; Hayashi et al., 2002*), IUGR (*Schjetlein et al., 1999; Chaiworapongsa et al., 2002; Hayashi et al., 1998; Hayashi & Ohkura, 2002; Ballard & Marcus, 1972*), fetal demise (*Erez et al., 2009*), PTL (*Chaiworapongsa et al., 2002; Erez et al., 2009; Elovitz, Baron & Phillippe, 2001*) and preterm PROM (*Chaiworapongsa et al., 2002; Erez et al., 2009; Rosen et al., 2001*).

There are several possible explanations for the increased thrombin generation in these patients: (1) increased activation of coagulation cascade in the maternal circulation due to pathological processes including bleeding or inflammation; and (2) depletion of anticoagulation proteins that subsequently leads to increased thrombin generation ([Table 1](#)).

Increased activation of the coagulation cascade and thrombin generation in the maternal circulation in patients with pregnancy complications

All the obstetrical syndromes including preeclampsia (*Schjetlein et al., 1999; Chaiworapongsa et al., 2002; Hayashi et al., 1998; Kobayashi & Terao, 1987; Hayashi et al., 2002; Kobayashi et al., 1999; Kobayashi et al., 2002*), IUGR (*Chaiworapongsa et al., 2002; Hayashi et al., 1998; Hayashi & Ohkura, 2002; Ballard & Marcus, 1972*), fetal demise (*Erez et al., 2009*), PTL (*Chaiworapongsa et al., 2002; Elovitz, Baron & Phillippe, 2001*) and preterm PROM (*Chaiworapongsa et al., 2002; Erez et al., 2009; Rosen et al., 2001*) are associated with a higher maternal thrombin generation than a normal pregnancy. These may be of clinical implication since, in women with preterm labor, elevated maternal plasma TAT III complex concentration was associated with a higher chance to deliver within <7 days from admission (*Erez et al., 2009*) ([Fig. 1](#)). To further understand how thrombin affects the duration of pregnancy and the clinical phenotype of patients with the obstetrical syndromes we need to consider what mechanisms lead to thrombin generation and how it affects the fetomaternal unit.

Increased thrombin generation can result from the following underlying mechanisms: (1) decidual hemorrhage that leads to a retro-placental clot formation (*Lockwood et al., 2005*); (2) intra-amniotic infection/inflammation which can induce decidual bleeding and sub-clinical abruption (*Gómez et al., 2005*), as well as increased intra-amniotic TAT complexes (*Erez et al., 2009*); and (3) an increased maternal systemic inflammatory response (*Gervasi et al., 2002*) that may activate the extrinsic pathway of coagulation due to the expression and release of TF by activated monocytes (*Østerud & Bjørklid, 2006*).

Thrombin affects many systems including also the following: (1) stimulation of decidual cell secretion of matrix metalloproteinases (MMP) (i.e., MMP-1 and MMP-3) that can degrade the extracellular matrix of the chorioamniotic membranes (*Rosen et al., 2002; Mackenzie et al., 2004*) (as in preterm PROM); (2) myometrial activation and uterine contractions generation that may lead to preterm labor with or without rupture of

Table 1 Concentration and activity in maternal plasma of coagulating and anticoagulating factors and their relation with thrombin generation in the great obstetrical syndromes.

	TF concentration and/or activity	TFPI concentration and/or activity	TAT III complexes concentration	Protein Z concentration	Thrombin generation	References
Premature rupture of membranes	Activity ↑ Concentration ↑	Concentration ↓	Concentration ↑	Concentration ↓	↑	(Erez et al., 2010; Erez et al., 2009; Kusanovic et al., 2007; Gris et al., 2002; Paidas et al., 2005)
Preterm labor	Activity ↑ Concentration =	Activity = Concentration ↓	Concentration ↑	Concentration ↓	↑	(Erez et al., 2010; Erez et al., 2009; Kusanovic et al., 2007; Gris et al., 2002; Paidas et al., 2005)
Fetal demise	Activity = Concentration =	Activity = Concentration ↓	Concentration ↑	Concentration ↓	↑	(Erez et al., 2010; Erez et al., 2009; Kusanovic et al., 2007; Gris et al., 2002; Paidas et al., 2005)
Preeclampsia	Activity ↑ Concentration ↑	Concentration ↑	Concentration ↑	Concentration ↓	↑	(Erez et al., 2010; Erez et al., 2009; Kusanovic et al., 2007; Gris et al., 2002; Paidas et al., 2005)
Intrauterine growth retardation/small for gestational age	Activity ↑ Concentration ↓	Concentration =	Concentration ↑	Concentration ↓	↑	(Erez et al., 2010; Erez et al., 2009; Kusanovic et al., 2007; Gris et al., 2002; Paidas et al., 2005)




Figure 1 Thrombin-antithrombin (TAT) III levels in control patients, patients with preterm labor who delivered between 21 and 7 days, and patients with preterm labor who delivered within 7 days from admission. Open diamonds, mean levels; black error bars, SD. * $P < .05$, Student-Newman-Keuls method. From *Elovitz, Baron & Phillippe (2001)*.

membranes and a subsequent preterm delivery (*Elovitz, Baron & Phillippe, 2001; Elovitz et al., 2000a; Elovitz et al., 2000b*); and (3) thrombin has an inhibitory effect on the production of TFPI by endothelial cells (*Bilsel et al., 2000*), and the increased thrombin generation observed in patients with PTL may be associated with a concomitant reduction in TFPI production by the maternal vascular endothelium (the depletion of anticoagulant proteins will be discussed in the following section of this review).

There is evidence to support that the extrinsic pathway of coagulation is activated in many of these pregnancy complications and it is the source of the increased thrombin generation (*VanWijk et al., 2002*). Indeed, increased immunoreactive TF concentrations were reported in women with preeclampsia and those with preterm PROM (*Erez et al., 2010*). Moreover, the contribution of preeclampsia to elevated maternal immunoreactive TF persisted also among patients with fetal demise, while those with fetal death who were normotensive did not have higher median TF concentration than normal pregnant women. Indeed, the median TF concentration of patients with preeclampsia was higher than in patients with fetal demise without hypertension. These findings are consistent with previous studies (*Bellart et al., 1998; Erez et al., 2008*), suggesting that elevated TF immunoreactivity and activity may be associated with the pathophysiologic process leading to preeclampsia, rather than being a consequence of the fetal death.

In some of the obstetrical syndromes there was elevated TF activity in the maternal circulation without a concomitant increase in the plasma concentration of this factor. This was the case among patients with a small for gestational age (SGA) neonate and those with preterm labor (*Chaiworapongsa et al., 2002; Erez et al., 2009*) (Table 1). This suggests that the increased TF activity among patients with PTL as well as those with an SGA neonate, contributes to a higher generation of factor Xa that, along with the physiologic increase in the maternal plasma concentrations of factor VII and factor X during gestation (*Bremme,*

2003; Beller & Ebert, 1982; Stirling et al., 1984; Brenner, 2004), may be the underlying mechanism leading to the increased thrombin generation reported these syndromes.

The differences between PTL and preterm PROM in term of maternal plasma TF concentration and activity may derive from the specific component of the common pathway of parturition, which is activated in each obstetrical syndrome (Romero et al., 2006). While preterm PROM is associated with the activation of the decidua and the membranes, myometrial activation is the major component of preterm labor with intact membranes (Romero et al., 2006). This is relevant because the decidua and the membranes have a high TF concentration (Lockwood, Krikun & Schatz, 2001; Lockwood, Krikun & Schatz, 1999; Lockwood et al., 2007).

In summary, the evidence brought herein suggests that increased thrombin generation in patients with the great obstetrical syndromes may reflect the activation of the coagulation cascade mainly through the extrinsic arm. This activation can be attributed to various underlying mechanisms.

Depleted or insufficient anticoagulant proteins concentration

In the normal state there is a delicate balance between the proteins activating/participating the coagulation cascade and their inhibitors. Increased thrombin generation may result, as we presented above, from activation of the coagulation cascade due to higher concentrations or activities of the proteins included in the coagulation cascade. However, thrombin generation can also result from insufficient concentration or activity of anticoagulation proteins.

Tissue factor pathway inhibitor (TFPI), a glycoprotein comprising of three Kunitz domains (Broze et al., 1988) that are specific inhibitors of trypsin-like proteinases (Laskowski & Kato, 1980), is the main inhibitor of the extrinsic pathway of coagulation. TFPI inhibits thrombin generation through the inactivation of activated factor X and the factor VIIa/TF complex (Broze et al., 1988; Broze, Girard & Novotny, 1990). The mean maternal plasma concentrations of total TFPI increases during the first half of pregnancy, remains relatively constant in the second half (Sarig et al., 2005) and decreases during labor (Uszyński et al., 2001). There are two types of TFPI: (1) TFPI-1 is the more prevalent form in the non-pregnant state in the maternal circulation and can also be found in the fetal blood, platelets, endothelial cells and other organs (Edstrom, Calhoun & Christensen, 2000; Tay, Cheong & Boo, 2003); and (2) TFPI-2- the major form of TFPI in the placenta (Hubé et al., 2003; Iino, Foster & Kisiel, 1998; Sprecher et al., 1994; Udagawa et al., 1998), also known as Placental Protein 5 (PP5) (Kamei et al., 2001; Kisiel, Sprecher & Foster, 1994). During pregnancy, the maternal plasma concentration of TFPI-2 increases gradually, reaches a plateau at 36 weeks and subsides after delivery (Bützow et al., 1988; Chand, Foster & Kisiel, 2005; Seppälä, Wahlström & Bohn, 1979; Obiewke & Chard, 1981).

The overall balance between the concentration and activity of the coagulation factors and the anticoagulation proteins is one of the determining factors of thrombin generation. In the normal state, the immunoreactive concentrations of TFPI in the plasma are 500 to 1,000 times higher than that of TF (Shimura et al., 1997), suggesting that an excess of anticoagulant proteins closely control the coagulation cascade activity. The median




Figure 2 (A) Comparison of median maternal plasma TF concentration between patients with normal pregnancy ($n = 79$), pre-eclampsia ($n = 133$), and women who delivered an SGA neonate ($n = 61$). (B) Comparison of median maternal plasma TFPI concentration between patients with normal pregnancy ($n = 86$), pre-eclampsia ($n = 133$), and women who delivered an SGA neonate ($n = 61$). (C) Comparison of maternal plasma TFPI/TF ratio between women with normal pregnancy ($n = 79$), pre-eclampsia ($n = 133$), and women who delivered an SGA neonate ($n = 61$). From [Erez et al. \(2008\)](#).

maternal plasma TFPI concentration increases during preeclampsia ([Erez et al., 2008](#); [Abdel Gader et al., 2006](#)), which is associated with an exaggerated maternal systemic inflammatory response. However, the increase in the median maternal TF plasma concentration is such that the overall balance between TF and its inhibitor is affected, leading to increased thrombin generation in this syndrome. In contrast to preeclampsia, maternal plasma TFPI concentration decreases in patients with PTL ([Erez et al., 2010](#)) and preterm PROM ([Erez et al., 2008](#)) regardless to the presence of intra-amniotic infection/inflammation, as well as in women with fetal demise ([Erez et al., 2009](#)), and does not change in mothers with SGA fetuses ([Erez et al., 2008](#)). Overall these findings suggest that the increased thrombin generation observed among these patients may derive not only from an increased activation of the hemostatic system, but also from insufficient anticoagulation, as reflected by the lower TFPI concentrations ([Fig. 2](#)).

A possible explanation of the lower maternal plasma concentration observed in some of the obstetrical syndromes may be that during these syndromes there is a reduction in the placental production of TFPI ([Hubé et al., 2003](#); [Iino, Foster & Kisiel, 1998](#); [Kamei et al., 2001](#); [Abdel Gader et al., 2006](#)) (mainly TFPI-2), contributing to the low maternal plasma concentrations detected in patients with PTL, in addition to the thrombin inhibitory effect to TFPI expression on endothelial cells, as above mentioned. Indeed, patients with vascular complications of pregnancy (preeclampsia, eclampsia, placental abruption, fetal growth restriction, and fetal demise) have a lower placental concentration of total TFPI, and TFPI mRNA expression than in women with normal pregnancies ([Xiong et al., 2010](#); [Aharon et al., 2005](#)).

Other proteins implicated in the inhibitory control of the coagulation cascade are protein S, protein C and protein Z. Protein S is a cofactor to protein C in the inactivation of factors Va and VIIIa. This protein exists in two forms: a free form and a complex form bound to complement protein C4b-binding protein (C4BP). Only the free form is

active (Castoldi & Hackeng, 2008). Protein S also acts as a TFPI cofactor, in the presence of weak procoagulant stimuli, by enhancing the interaction of TFPI with factor Xa while using Ca^{2+} and phospholipids in the process (Hackeng et al., 2006) without increasing inhibition of factor VIIa-TF by TFPI (Ndonwi & Broze, 2008). During pregnancy there is a physiologic change in the relationship between the bound and the free forms of protein S in the maternal plasma. The increase in C4BP during gestation reduces free protein S concentration in up to 55% of its value out of pregnant state, reaching its nadir at delivery. Of interest, cesarean delivery and infection exacerbate the reduction in free protein S concentrations (Bremme, 2003; Faught et al., 1995). Moreover, a functional protein S deficiency can explain a poor response to activated protein C (Dahlbäck, Carlsson & Svensson, 1993).

The association between the alteration of concentration and function of protein S and protein C in the great obstetrical syndromes is not completely clear. The evidence regarding the association of protein S and protein C deficiency and preeclampsia is controversial (Rodger et al., 2008; Yalinkaya et al., 2006).

While some reported an association between protein S deficiency and an increased risk for this syndrome (especially for early onset preeclampsia) (Rodger et al., 2008) others could not demonstrate this effect (Yalinkaya et al., 2006). There is some evidence regarding the relation of protein S deficiency and increased risk of stillbirth (Preston et al., 1996) and mid-trimester IUGR (Kupferminc et al., 2002). An increased risk of stillbirth has been reported in patients with protein S deficiency while the risk was not significantly increased in cases of protein C deficiency (Preston et al., 1996), and Kupferminc et al. (2002) found that protein S, but not protein C deficiency, was significantly associated with severe mid-trimester IUGR.

Protein Z, in complex with protein Z-dependent protease inhibitor (ZPI) (Fig. 3) (Han, Fiehler & Broze, 1998; Han et al., 1999; Han, Fiehler & Broze, 2000), acts as a physiologic inhibitor of activation of prothrombin by factor Xa. Protein Z is a vitamin K-dependent plasma glycoprotein (Yin et al., 2000) that is an essential cofactor for ZPI activity. In the absence of protein Z, the activity of ZPI is reduced by more than 1,000-fold (Han, Fiehler & Broze, 2000). Normal pregnancy is characterized by an increased plasma concentration of protein Z (Taylor et al., 1998), probably as a compensation for the increase of factor X concentration. Women with preterm labor without intra-amniotic infection or inflammation and those with vaginal bleeding who delivered preterm had a lower median maternal plasma protein Z concentration than women with a normal pregnancy and those with vaginal bleeding who delivered at term (Kusanovic et al., 2007). The changes of protein Z concentrations in other pregnancy complications are controversial. Some demonstrated that the median plasma concentration of protein Z in patients with preeclampsia, IUGR, and late fetal death were not significantly different than that of patients with a normal pregnancy (Bretelle et al., 2005). Others reported lower median maternal plasma protein Z concentrations in women with preeclampsia or pyelonephritis and higher proportion of protein Z deficiency (defined as protein Z plasma concentration below the 5th percentile) in patients with preeclampsia or fetal demise than in those with a normal pregnancy (Nien et al., 2008). Moreover, increased maternal plasma




Figure 3 Factor X activation and protein Z/protein Z-dependent protease inhibitor (ZPI) inhibition of activated factor X. (A) The formation of the complex of tissue factor (TF) and factor VIIa (FVIIa) at the site of injury and activation of extrinsic coagulation cascade. (B) Activation of circulating factor X by the TF/VIIa complex in the presence of exposed phospholipids and Ca²⁺. (C) Inhibition of factor Xa (FXa) by the protein Z/ZPI complex by binding to its active site. Modified from *Broze (2001)*.

anti-protein Z antibodies concentrations were associated with SGA neonates, fetal demise and preeclampsia.

The information presented above suggests that it is not only the concentration of one coagulation factor or anticoagulation protein, but rather the overall balance between the coagulation factors and their inhibitors that increases thrombin generation in the great obstetrical syndromes. Indeed, although preterm labor was not associated with a significant change in the median maternal plasma TF concentration, the TFPI/TF ratio of these patients was lower than that of normal pregnant women, mainly due to decreased TFPI concentrations.

This observation was also reported in patients with preterm PROM (*Erez et al., 2008*), and those with preeclampsia (*Erez et al., 2008*). The lower TFPI/TF ratio in patients with preeclampsia occurs despite the increase in the median maternal plasma TFPI concentration observed in these patients. This suggests that the balance between TF and its natural inhibitor may better reflect the overall activity of the TF pathway of coagulation, than the individual concentrations of TF or TFPI.

Collectively, these observations suggest that our attention should be focused not only on the coagulation protein but also on their inhibitors since an imbalance between them may contribute to increased thrombin generation leading to the onset of the great obstetrical syndromes.

Changes in the feto-maternal interface

Normal placental development and the establishment of an adequate feto-maternal circulation are key points for a successful pregnancy. The networks of the placental vascular tree either on the maternal or fetal side are dynamic structures that can be substantially altered in cases of abnormal placentation and trophoblast invasion. The human trophoblast has properties of endothelial cells and can regulate the degree of activation of the coagulation cascade in the intervillous space (*Sood et al., 2006; Sood et al., 2008*). The villous trophoblasts express heparin sulfate, protein C and protein Z on their surface that serve as anticoagulant that sustain laminar blood flow through the intervillous space. On the other hand, unlike the endothelium of other organs, the trophoblast constantly presents the active placental isoform of TF on its surface (*Sood et al., 2008; Lanir, Aharon & Brenner, 2003; Isermann et al., 2003; Aharon et al., 2004*). This isoform has a higher affinity for factor VIIa (*Butenas & Orfeo, 2007*), which may lead to increased activation of the coagulation cascade. One of the leading pathological processes observed in all these syndromes is thrombosis and vascular abnormality of the placenta at the maternal–fetal interface. The incidence of these pathological processes varies among the different syndromes being more prevalent in preeclampsia, IUGR, and fetal demise than in PTL and preterm PROM (*Schjetlein et al., 1999; Chaiworapongsa et al., 2002; Erez et al., 2009; Elovitz, Baron & Phillippe, 2001*).

Placental pathology in the great obstetrical syndromes

There is a range of placental vascular and thrombotic lesions that are being observed in placentas of patients with pregnancy complications. Thrombotic events of placental vessels can cause an impairment of placental perfusion, leading to fetal growth restriction (FGR), preeclampsia and fetal death as well as in some extents to PTL and preterm PROM (*Midderdorp, 2007; Martinelli et al., 2001*). The frequency of the specific vascular placental lesions varies among these obstetrical syndromes (*Kovo, Schreiber & Bar, 2013*).

Placental vascular lesions are divided into maternal or fetal vascular origin (*Figs. 4 and 5*) (*Redline et al., 2005; Bar et al., 2012*). Lesions of the maternal vascular compartment include placental marginal and retro-placental hemorrhages, lesions related to maternal underperfusion (acute atherosclerosis and mural hypertrophy, increased syncytial knots, villous agglutination, increased intervillous fibrin deposition, villous infarcts) (*Redline et al.,*




Figure 4 Histologic features of maternal vessels and implantation site reaction patterns. (A) Acute atherosclerosis of maternal arterioles in the placental membranes: a cluster of decidual arterioles shows varying stages of fibrinoid necrosis. The vessel at the upper right shows full histologic expression with dark homogenous fibrinoid replacement of the vessel wall accompanied by occasional foamy macrophages ([original magnification is indicated for all panels] X 20). (B) Mural hypertrophy of decidual arterioles in the placental membranes: a cluster of arterioles shows medial hypertrophy with the vessel wall occupying greater than one third of total vessel diameter (X 10). (C) Muscularized basal plate arteries with accompanying implantation site abnormalities: maternal spiral arteries in the basal plate lack normal trophoblast remodeling and retain their pre-pregnancy muscular media. Clusters of immature intermediate trophoblast and increased placental giant cells are seen above and below the muscular arteries, respectively (X 10). (D) Acute atherosclerosis of muscularized basal plate arteries with accompanying implantation site abnormalities: three cross sections of a basal plate artery ([continued on next page...](#))

Figure 4 (...continued)

are seen. The two on the left show persistence of the muscular media while the one on the right has undergone fibrinoid necrosis of the media with foamy macrophages (acute atherosclerosis). Clusters of immature intermediate trophoblast are also seen overlying the arteries (X 4). (E) Immature intermediate trophoblast: clusters of abnormally small intermediate trophoblast with focal vacuolation are surrounded by an excessive amount of basal plate fibrin. Increased placental site giant cells are also seen at the lower margin (X 10). (F) Increased placental site giant cells: numerous multinucleate placental site giant cells, not usually seen in the delivered placenta, are scattered in loose decidual tissue which is devoid of normal intermediate trophoblast and fibrinoid (X 10). From *Redline et al. (2004)*.

2005). Placental fetal vascular obstructive lesions are the result of stasis, hypercoagulability and vascular damage within the fetal circulation of the placenta. Placental fetal vascular abnormalities include: cord-related abnormalities (as torsion of cord, over-coiling, strictures and tight knots (*Cromi et al., 2005*)) and vascular lesions consistent with fetal thrombo-occlusive disease (thrombosis of the chorionic plate and stem villous vessels, fibrotic, hypo-vascular and avascular villi (*Redline et al., 2005*)). In addition, villitis of unknown etiology or chronic villitis, defined as lymphohistiocytic inflammation localized to the stroma of terminal villi but often extending to the small vessels of upstream villi is also associated with obliterative fetal vasculopathy (*Redline et al., 2005*) (Figs. 4 and 5).

Preeclampsia. The classic example for an association between obstetrical syndromes and vascular placental lesions is preeclampsia. Women who develop preeclampsia have an increased rate of abnormalities of the maternal side of the placental circulation and maternal underperfusion (*Salafia et al., 1998; Roberts & Post, 2008*). The frequency of these lesions is inversely related to the gestational age in which the hypertensive disorder was diagnosed. The earlier the development of hypertension/preeclampsia the more severe the vascular lesions are (*Mayhew et al., 2003; Ogge et al., 2011*). Moreover, *Kovo et al. (2010)* reported that the presence of fetal growth restriction in women with preeclampsia also increases the frequency of fetal vascular lesions. Indeed, patients with early-onset preeclampsia complicated by FGR had a higher rate of fetal vascular supply lesions consistent with fetal thrombo-occlusive disease than women with early onset disease without FGR (*Kovo et al., 2010*).

An assessment of the pathologic changes in placental hemostatic system has been performed in patients with preeclampsia. *Teng et al. (2010)* studied TF and TFPI placental levels in pregnant patients with preeclampsia, compared to normal pregnancies. They found increased TF placental expression and a reduced expression of TFPI-1 and TFPI-2, with a significant correlation between the levels of TF and TFPI-2 between maternal plasma and placenta.

Fetal growth restriction. Placentas from pregnancies complicated by FGR are smaller and have significantly increased maternal and fetal vascular lesions compared to placentas from normal pregnancies with appropriate for gestational age neonates (AGA) (*Redline, 2008; Salafia et al., 1995*). Maternal vascular lesions were detected in about 50% of placentas from pregnancies complicated with FGR at term, compared to only 20% in normal pregnancies, while fetal vascular lesions were observed in 11% of FGR pregnancies compared to only 4% in placentas from normal pregnancies (*Kovo et al., 2010*).




Figure 5 Histologic features of villous and intervillous lesions. (A) Increased syncytial knots: aggregates of syncytiotrophoblast nuclei cluster at one or more poles of distal villi in the vicinity of larger stem villi (arrowhead) at the periphery of the lobule ([original magnification is indicated for all panels] X 10). (B) Villous agglutination: clusters of degenerating distal villi are adherent to one another and focally enmeshed in fibrin (X 4). (C) Distal villous hypoplasia: a long, thin, non-branching stem villus is surrounded by a markedly reduced number of small hypoplastic distal villi (X 10). (D) Increased intervillous fibrin: stem villi are surrounded by a mantle of fibrin-type fibrinoid that does not extend to distal villi at the center of the lobule (X 2). (E) Nodular intervillous (and intravillous) fibrin: small aggregates of intervillous fibrin adhere to, and are focally reepithelialized by, distal villous trophoblast (X 20). (F) Increased intervillous fibrin with intermediate trophoblast (X-cells): stem and distal villi are enmeshed in a matrix of fibrin and fibrinoid containing prominent intermediate trophoblast (arrowhead) (X 10). From [Redline et al. \(2004\)](#).

Placentas from normotensive pregnancies complicated by early onset FGR (<34 weeks of gestation) had a higher rate of low placental weight (<10th percentile) and maternal underperfusion, as compared to placentas of women who delivered AGA neonates \leq 34 weeks of gestation (*Rerdline, 2008*). Of interest, placentas from the late onset FGR group (after 34 weeks of gestation), in addition to the high maternal vascular abnormalities, show also more fetal vascular abnormalities, compared with AGA controls who delivered >34 weeks (*Kovo et al., 2012*).

Fetal demise. Placental disease has been recognized as an important contributor to unexplained fetal demise. Fetal vascular abnormalities (*Kovo, Schreiber & Bar, 2013*) are extensively involved in early and late fetal death rather than maternal vascular lesions. In fetal death occurring prior to 34 weeks, an earlier and extended insult in the placental development occurs. On the other hand, late fetal demise is an unpredicted event that is mostly characterized by non-thrombotic cord related lesions and less placental vascular compromise (*Bar et al., 2012*).

Preterm labor and preterm PROM. Placental studies in PTL demonstrated a combination of inflammatory and vascular lesions. PTL is generally attributed to an inflammatory response involving the bacterial induction of cytokine and prostanoid production (*Romero et al., 2006*). Finding of histological chorioamnionitis in PTL (*Arias et al., 1993*) has established infection and inflammation as a causative factor of preterm birth, moreover, noninfectious trigger may also contribute to the development of preterm labor and in some instances may be evident by placental sterile inflammatory response (*Nath et al., 2007*). In addition, isolated placental vascular lesions, mostly of maternal supply, were reported in 20% of cases of PTL and an additional 20% had combined inflammatory and vascular lesions. Moreover, there are consistent reports describing increased rate of failure of transformation of the spiral arteries in women with preterm labor without intrauterine infection/inflammation and in those with preterm PROM than in women with normal pregnancies (*Kim et al., 2002*). Such findings imply that an inadequate uteroplacental blood flow due to abnormal placentation plays an important role in pathogenesis of preterm parturition (*Kim et al., 2002; Salafia & Vogel, 1991*).

Collectively, placental vascular lesions were reported in all the great obstetrical syndromes. The severity of these lesions is associated with the timing of diagnosis of the disease. The more severe the vascular injury, the more likely these complications will become clinically evident prior to 34 weeks of gestation. Of interest, vascular lesions often come along with evidence of acute inflammation or lesions associated with chronic inflammatory processes, suggesting that sometimes more than one mechanism is involved in the development of a specific obstetrical syndrome.

Hemostatic changes in the amniotic fluid of women with obstetrical syndromes

During normal pregnancy, there is an increase in the amniotic fluid TF concentration (*de Boer et al., 1989; Uszyński et al., 2001; Lockwood et al., 1991; Omsjøl et al., 1985; Creter, 1977*). In order to demonstrate the association of hemostatic changes and the development




Figure 6 (A) Amniotic fluid tissue factor concentration among women with normal pregnancies (median 3,710.4 pg/mL, range 2,198.8–6,268) and patients with a fetal demise (median 8,535.4 pg/mL, range 2,208.2–1,25,990.0). (B) Amniotic fluid tissue factor activity among women with normal pregnancies (median 28.4 pM, range 10.2–84.9) and patients with a fetal demise (median 81.6 pM, range 7.2–1,603.4). From *Erez et al. (2009)*.

of obstetrical complications, *Erez et al. (2009)* studied the changes in the intra-amniotic concentration of TAT III complexes, as well as TF concentration and activity, in cases of fetal demise and in normal pregnancies.

Patients with a fetal demise had higher median amniotic fluid TF concentration and activity than those with normal pregnancies. Moreover, among patients with fetal demise there was a significant correlation (*Fig. 6*) between the amniotic fluid TF concentrations and activity ($r = 0.88$, $P < 0.0001$). The median amniotic fluid TAT III complexes concentration did not differ significantly between the groups (normal pregnancy: median: 66.3 mg/L, range 11.4–2,265.4 vs. fetal demise median: 59.3 mg/L, range: 13.6–15,425.3; $P = 0.7$). In their study, the median amniotic fluid TF concentration in normal pregnant women was 10 fold higher than in maternal plasma.

The changes in amniotic fluid thrombin generation were reported also in women with preterm parturition. Indeed, intra-amniotic infection and/or inflammation is associated with an increased amniotic fluid TAT III complexes (*Fig. 7*). This is important since it represents an increased thrombin generation in the amniotic cavity during infection and/or inflammation that may contribute to uterine contractility and the development of preterm birth (*Stephenson et al., 2005*). Of interest, elevated intra-amniotic TAT III concentrations were associated with a shorter amniocentesis to delivery interval and an earlier gestational age at delivery only in patients with preterm labor without intra-amniotic infection or inflammation (*Stephenson et al., 2005*). This observation suggests that in a subset of patients with preterm labor, activation of the coagulation system can generate preterm parturition and delivery; while in those with intra-amniotic infection and/or inflammation the activation of the coagulation and thrombin generation is a byproduct of the inflammatory process leading to preterm birth.




Figure 7 Maternal plasma TAT III concentration in women with preterm labor (PTL) and those with a normal pregnancy. From *Chaiworapongsa et al. (2002)*.

This represents evidence of the activation and propagation of coagulation cascade, being thrombin generation the witness of the former mechanisms and the inhibitor of the initiation step (*Erez et al., 2009*).

CONCLUSION

The evidence presented herein suggests a role for increased thrombin generation and vascular placental lesions in the pathogenesis of the great obstetrical syndromes. This process can be the result of the contribution of procoagulant and vascular abnormalities as well as inflammatory and infectious mechanisms, representing the starting point for pregnancy complications based on vascular disease.

As presented, these changes affect the mother, the placenta, the membranes and the amniotic fluid. Moreover, preliminary evidence suggests that some of the changes in the hemostatic system in the mother and in the amniotic fluid predate the clinical presentation of the disease. This means that better understanding of the vascular and coagulation changes associated with the great obstetrical syndromes may assist us in earlier detection and the development or introduction of therapeutic modalities for these syndromes.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors declare there was no funding for this work.

Competing Interests

Offer Erez is an Academic Editor for PeerJ.

Author Contributions

- Salvatore Andrea Mastrolia, Moshe Mazor, Giuseppe Loverro, Vered Klaitman and Offer Erez wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

REFERENCES

- Abdel Gader AM, Al-Mishari AA, Awadalla SA, Buyuomi NM, Khashoggi T, Al-Hakeem M. 2006. Total and free tissue factor pathway inhibitor in pregnancy hypertension. *International Journal of Gynaecology and Obstetrics* 95:248–253 DOI 10.1016/j.ijgo.2006.07.014.
- Aharon A, Brenner B, Katz T, Miyagi Y, Lanir N. 2004. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. *Thrombosis and Haemostasis* 92:776–786.
- Aharon A, Lanir N, Drugan A, Brenner B. 2005. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. *Journal of Thrombosis and Haemostasis* 3:2355–2357 DOI 10.1111/j.1538-7836.2005.01564.x.
- Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U. 1996. Thrombin-inhibitor complexes in the blood during and after delivery. *Thrombosis Research* 82:109–117 DOI 10.1016/0049-3848(96)00057-6.
- Arias F, Rodriquez L, Rayne SC, Kraus FT. 1993. Maternal placental vasculopathy and infection: two distinct subgroups among patients with preterm labor and preterm ruptured membranes. *American Journal of Obstetrics and Gynecology* 168:585–591 DOI 10.1016/0002-9378(93)90499-9.
- Ballard HS, Marcus AJ. 1972. Primary and secondary platelet aggregation in uraemia. *Scandinavian Journal of Haematology* 9:198–203 DOI 10.1111/j.1600-0609.1972.tb00931.x.
- Bar J, Schreiber L, Ben-Haroush A, Ahmed H, Golan A, Kovo M. 2012. The placental vascular component in early and late intrauterine fetal death. *Thrombosis Research* 130:901–905 DOI 10.1016/j.thromres.2012.09.013.
- Bellart J, Gilabert R, Miralles RM, Monasterio J, Cabero L. 1998. Endothelial cell markers and fibrinopeptide A to D-dimer ratio as a measure of coagulation and fibrinolysis balance in normal pregnancy. *Gynecologic and Obstetric Investigation* 46:17–21 DOI 10.1159/000009989.
- Beller FK, Ebert C. 1982. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 13:177–197 DOI 10.1016/0028-2243(82)90028-4.
- Bilsel AS1, Onaran N, Moini H, Emerk K. 2000. Long-term effect of 17beta-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC. *Thrombosis Research* 99:173–178 DOI 10.1016/S0049-3848(00)00228-0.
- Bremme KA. 2003. Haemostatic changes in pregnancy. *Best Practice & Research Clinical Haematology* 16:153–168 DOI 10.1016/S1521-6926(03)00021-5.
- Brenner B. 2004. Haemostatic changes in pregnancy. *Thrombosis Research* 114:409–414 DOI 10.1016/j.thromres.2004.08.004.
- Bretelle F, Arnoux D, Shojai R, D'Ercole C, Sampol J, Dignat F, Camoin-Jau L. 2005. Protein Z in patients with pregnancy complications. *American Journal of Obstetrics and Gynecology* 193:1698–1702 DOI 10.1016/j.ajog.2005.04.006.
- Broze JG. 2001. Protein-Z and thrombosis. *Lancet* 357:900–901 DOI 10.1016/S0140-6736(00)04229-X.
- Broze GJ, Girard TJ, Novotny WF. 1990. Regulation of coagulation by a multivalent Kunitz-type inhibitor. *Biochemistry* 29:7539–7546 DOI 10.1021/bi00485a001.
- Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. 1988. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. *Blood* 71:335–343.

- Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. 2007.** Tissue factor in thrombosis and hemorrhage. *Surgery* **142**:S2–S14 DOI [10.1016/j.surg.2007.06.032](https://doi.org/10.1016/j.surg.2007.06.032).
- Bützow R, Virtanen I, Seppälä M, Närvänen O, Stenman UH, Ristimäki A, Bohn H. 1988.** Monoclonal antibodies reacting with placental protein 5: use in radioimmunoassay, Western blot analysis, and immunohistochemistry. *Journal of Laboratory and Clinical Medicine* **111**:249–256.
- Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Müller M, Risau W, Edgington T, Collen D. 1996.** Role of tissue factor in embryonic blood vessel development. *Nature* **383**:73–75 DOI [10.1038/383073a0](https://doi.org/10.1038/383073a0).
- Castoldi E, Hackeng TM. 2008.** Regulation of coagulation by protein S. *Current Opinions in Hematology* **15**:529–536 DOI [10.1097/MOH.0b013e328309ec97](https://doi.org/10.1097/MOH.0b013e328309ec97).
- Chaiworapongsa T, Espinoza J, Yoshimatsu J, Kim YM, Bujold E, Edwin S, Yoon BH, Romero R. 2002.** Activation of coagulation system in preterm labor and preterm premature rupture of membranes. *Journal of Maternal–Fetal and Neonatal Medicine* **11**(6):368–373 DOI [10.1080/jmf.11.6.368.373](https://doi.org/10.1080/jmf.11.6.368.373).
- Chaiworapongsa T, Yoshimatsu J, Espinoza J, Kim YM, Berman S, Edwin S, Yoon BH, Romero R. 2002.** Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. *Journal of Maternal–Fetal and Neonatal Medicine* **11**:362–367 DOI [10.1080/jmf.11.6.362.367](https://doi.org/10.1080/jmf.11.6.362.367).
- Chand HS, Foster DC, Kisiel W. 2005.** Structure, function and biology of tissue factor pathway inhibitor-2. *Thrombosis and Haemostasis* **94**:1122–1130.
- Concise Medical Dictionary. 2010.** Oxford: Oxford University Press.
- Creter D. 1977.** Amnioplastin: new reagent for coagulation tests. *Lancet* **2**:251 DOI [10.1016/S0140-6736\(77\)92871-9](https://doi.org/10.1016/S0140-6736(77)92871-9).
- Cromi A, Ghezzi F, Dürig P, Di Naro E, Raio L. 2005.** Sonographic umbilical cord morphometry and coiling patterns in twin-twin transfusion syndrome. *Prenatal Diagnosis* **25**:851–855 DOI [10.1002/pd.1273](https://doi.org/10.1002/pd.1273).
- Dahlbäck B, Carlsson M, Svensson PJ. 1993.** Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. *Proceedings of the National Academy of Sciences of the United States of America* **90**:1004–1008 DOI [10.1073/pnas.90.3.1004](https://doi.org/10.1073/pnas.90.3.1004).
- de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE. 1989.** Enhanced thrombin generation in normal and hypertensive pregnancy. *American Journal of Obstetrics and Gynecology* **160**:95–100 DOI [10.1016/0002-9378\(89\)90096-3](https://doi.org/10.1016/0002-9378(89)90096-3).
- Edstrom CS, Calhoun DA, Christensen RD. 2000.** Expression of tissue factor pathway inhibitor in human fetal and placental tissues. *Early Human Development* **59**:77–84 DOI [10.1016/S0378-3782\(00\)00084-0](https://doi.org/10.1016/S0378-3782(00)00084-0).
- Eichinger S, Weltermann A, Philipp K, Hafner E, Kaider A, Kittl EM, Brenner B, Mannhalter C, Lechner K, Kyrle PA. 1999.** Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. *Thrombosis and Haemostasis* **82**:1232–1236.
- Elovitz MA, Ascher-Landsberg J, Saunders T, Phillippe M. 2000a.** The mechanisms underlying the stimulatory effects of thrombin on myometrial smooth muscle. *American Journal of Obstetrics and Gynecology* **183**:674–681 DOI [10.1067/mob.2000.106751](https://doi.org/10.1067/mob.2000.106751).
- Elovitz MA, Baron J, Phillippe M. 2001.** The role of thrombin in preterm parturition. *American Journal of Obstetrics and Gynecology* **185**:1059–1063 DOI [10.1067/mob.2001.117638](https://doi.org/10.1067/mob.2001.117638).

- Elovitz MA, Saunders T, Ascher-Landsberg J, Phillippe M. 2000b. Effects of thrombin on myometrial contractions *in vitro* and *in vivo*. *American Journal of Obstetrics and Gynecology* 183:799–804 DOI 10.1067/mob.2000.108897.
- Erez O, Espinoza J, Chaiworapongsa T, Gotsch F, Kusanovic JP, Than NG, Mazaki-Tovi S, Vaisbuch E, Papp Z, Yoon BH, Han YM, Hoppensteadt D, Fareed J, Hassan SS, Romero R. 2008. A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor. *Journal of Maternal–Fetal and Neonatal Medicine* 21:732–744 DOI 10.1080/14767050802361807.
- Erez O, Gotsch F, Mazaki-Tovi S, Vaisbuch E, Kusanovic JP, Kim CJ, Chaiworapongsa T, Hoppensteadt D, Fareed J, Than NG, Nhan-Chang CL, Yeo L, Pacora P, Mazor M, Hassan SS, Mittal P, Romero R. 2009. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. *Journal of Maternal–Fetal and Neonatal Medicine* 22:672–687 DOI 10.1080/14767050902853117.
- Erez O, Romero R, Hoppensteadt D, Than NG, Fareed J, Mazaki-Tovi S, Espinoza J, Chaiworapongsa T, Kim SS, Yoon BH, Hassan SS, Gotsch F, Friel L, Vaisbuch E, Kusanovic JP. 2008. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. *Journal of Maternal–Fetal and Neonatal Medicine* 21:855–869 DOI 10.1080/14767050802361872.
- Erez O, Romer R, Vaisbuch E, Chaiworapongsa T, Kusanovic JP, Mazaki-Tovi S, Gotsch F, Gomez R, Maymon E, Pacora P, Edwin SS, Kim CJ, Than NG, Mittal P, Yeo L, Dong Z, Yoon BH, Hassan SS, Mazor M. 2009. Changes in amniotic fluid concentration of thrombin–antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation. *Journal of Maternal–Fetal and Neonatal Medicine* 22:971–982 DOI 10.3109/14767050902994762.
- Erez O, Romero R, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Chaiworapongsa T, Gotsch F, Fareed J, Hoppensteadt D, Than NG, Yoon BH, Edwin S, Dong Z, Espinoza J, Mazor M, Hassan SS. 2010. High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor. *Journal of Maternal–Fetal and Neonatal Medicine* 23:23–33 DOI 10.3109/14767050902994770.
- Erlich J, Parry GC, Fearn C, Muller M, Carmeliet P, Luther T, Mackman N. 1999. Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation. *Proceedings of the National Academy of Sciences of the United States of America* 96:8138–8143 DOI 10.1073/pnas.96.14.8138.
- Faught W, Garner P, Jones G, Ivey B. 1995. Changes in protein C and protein S levels in normal pregnancy. *American Journal of Obstetrics and Gynecology* 172:147–150 DOI 10.1016/0002-9378(95)90104-3.
- Gervasi MT, Chaiworapongsa T, Naccasha N, Pacora P, Berman S, Maymon E, Kim JC, Kim YM, Yoshimatsu J, Espinoza J, Romero R. 2002. Maternal intravascular inflammation in preterm premature rupture of membranes. *Journal of Maternal–Fetal and Neonatal Medicine* 11:171–175 DOI 10.1080/jmf.11.3.171.175.
- Gómez R, Romero R, Nien JK, Medina L, Carstens M, Kim YM, Chaiworapongsa T, Espinoza J, González R. 2005. Idiopathic vaginal bleeding during pregnancy as the only clinical manifestation of intrauterine infection. *Journal of Maternal–Fetal and Neonatal Medicine* 18:31–37 DOI 10.1080/14767050500217863.
- Gris JC, Quere I, Dechaud H, Mercier E, Pincon C, Hoffet M, Vasse M, Mares P. 2002. High frequency of protein Z deficiency in patients with unexplained early fetal loss. *Blood* 99:2606–2608 DOI 10.1182/blood.V99.7.2606.

- Hackeng TM, Seré KM, Tans G, Rosing J. 2006.** Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. *Proceedings of the National Academy of Sciences of the United States of America* **103**:3106–3111 DOI [10.1073/pnas.0504240103](https://doi.org/10.1073/pnas.0504240103).
- Han X, Fiehler R, Broze GJ. 1998.** Isolation of a protein Z-dependent plasma protease inhibitor. *Proceedings of the National Academy of Sciences of the United States of America* **95**:9250–9255 DOI [10.1073/pnas.95.16.9250](https://doi.org/10.1073/pnas.95.16.9250).
- Han X, Fiehler R, Broze GJ. 2000.** Characterization of the protein Z-dependent protease inhibitor. *Blood* **96**:3049–3055.
- Han X, Huang ZF, Fiehler R, Broze Jr GJ. 1999.** The protein Z-dependent protease inhibitor is a serpin. *Biochemistry* **38**:11073–11078 DOI [10.1021/bi990641a](https://doi.org/10.1021/bi990641a).
- Hayashi M1, Inoue T, Hoshimoto K, Negishi H, Ohkura T, Inaba N. 2002.** Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia. *European Journal of Haematology* **69**:297–302 DOI [10.1034/j.1600-0609.2002.02691.x](https://doi.org/10.1034/j.1600-0609.2002.02691.x).
- Hayashi M, Numaguchi M, Ohkubo N, Yaoi Y. 1998.** Blood macrophage colony-stimulating factor and thrombin–antithrombin III complex concentrations in pregnancy and preeclampsia. *American Journal of the Medical Sciences* **315**:251–257 DOI [10.1097/00000441-199804000-00007](https://doi.org/10.1097/00000441-199804000-00007).
- Hayashi M, Ohkura T. 2002.** Elevated levels of serum macrophage colony-stimulating factor in normotensive pregnancies complicated by intrauterine fetal growth restriction. *Experimental Hematology* **30**:388–393 DOI [10.1016/S0301-472X\(02\)00790-7](https://doi.org/10.1016/S0301-472X(02)00790-7).
- Holmes VA, Wallace JM. 2005.** Haemostasis in normal pregnancy: a balancing act? *Biochemical Society Transactions* **33**:428–432 DOI [10.1042/BST0330428](https://doi.org/10.1042/BST0330428).
- Hubé F, Reverdiau P, Iochmann S, Trassard S, Thibault G, Gruel Y. 2003.** Demonstration of a tissue factor pathway inhibitor 2 messenger RNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas. *Biology of Reproduction* **68**:1888–1894 DOI [10.1095/biolreprod.102.011858](https://doi.org/10.1095/biolreprod.102.011858).
- Iino M, Foster DC, Kisiel W. 1998.** Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. *Arteriosclerosis, Thrombosis, and Vascular Biology* **18**:40–46 DOI [10.1161/01.ATV.18.1.40](https://doi.org/10.1161/01.ATV.18.1.40).
- Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, Mackman N, Weiler H. 2003.** The thrombomodulin-protein C system is essential for the maintenance of pregnancy. *Nature Medicine* **9**:331–337 DOI [10.1038/nm825](https://doi.org/10.1038/nm825).
- Kamei S, Kazama Y, Kuijper JL, Foster DC, Kisiel W. 2001.** Genomic structure and promoter activity of the human tissue factor pathway inhibitor-2 gene. *Biochimica et Biophysica ACTA/General Subjects* **1517**:430–435 DOI [10.1016/S0167-4781\(00\)00298-0](https://doi.org/10.1016/S0167-4781(00)00298-0).
- Kim YM, Chaiworapongsa T, Gomez R, Bujold E, Yoon BH, Rotmensch S, Thaler HT, Romero R. 2002.** Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. *American Journal of Obstetrics and Gynecology* **187**:1137–1142 DOI [10.1067/mob.2002.127720](https://doi.org/10.1067/mob.2002.127720).
- Kisiel W, Sprecher CA, Foster DC. 1994.** Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. *Blood* **84**:4384–4385.
- Kobayashi T, Sumimoto K, Tokunaga N, Sugimura M, Nishiguchi T, Kanayama N, Terao T. 2002.** Coagulation index to distinguish severe preeclampsia from normal pregnancy. *Seminars in Thrombosis and Hemostasis* **28**:495–500 DOI [10.1055/s-2002-36689](https://doi.org/10.1055/s-2002-36689).

- Kobayashi T, Terao T. 1987.** Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: thrombin–antithrombin III complex and D-dimers. *Gynecologic and Obstetric Investigation* **24**:170–178 DOI [10.1159/000298799](https://doi.org/10.1159/000298799).
- Kobayashi T, Tokunaga N, Sugimura M, Suzuki K, Kanayama N, Nishiguchi T, Terao T. 1999.** Coagulation/fibrinolysis disorder in patients with severe preeclampsia. *Seminars in Thrombosis and Hemostasis* **25**:451–454 DOI [10.1055/s-2007-994949](https://doi.org/10.1055/s-2007-994949).
- Kovo M, Schreiber L, Bar J. 2013.** Placental vascular pathology as a mechanism of disease in pregnancy complications. *Thrombosis Research* **131**(Suppl 1):S18–S21 DOI [10.1016/S0049-3848\(13\)70013-6](https://doi.org/10.1016/S0049-3848(13)70013-6).
- Kovo M, Schreiber L, Ben-Haroush A, Gold E, Golan A, Bar J. 2012.** The placental component in early-onset and late-onset preeclampsia in relation to fetal growth restriction. *Prenatal Diagnosis* **32**:632–637 DOI [10.1002/pd.3872](https://doi.org/10.1002/pd.3872).
- Kovo M, Schreiber L, Ben-Haroush A, Wand S, Golan A, Bar J. 2010.** Placental vascular lesion differences in pregnancy-induced hypertension and normotensive fetal growth restriction. *American Journal of Obstetrics and Gynecology* **202**:561.e1–561.e5 DOI [10.1016/j.ajog.2010.01.012](https://doi.org/10.1016/j.ajog.2010.01.012).
- Ku DH, Arkel YS, Paidas MP, Lockwood CJ. 2003.** Circulating levels of inflammatory cytokines (IL-1 beta and TNF-alpha), resistance to activated protein C, thrombin and fibrin generation in uncomplicated pregnancies. *Thrombosis and Haemostasis* **90**:1074–1079.
- Kuczyński J, Uszyński W, Zekanowska E, Soszka T, Uszyński M. 2002.** Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in the placenta and myometrium. *European Journal of Obstetrics & Gynecology and Reproductive Biology* **105**:15–19 DOI [10.1016/S0301-2115\(02\)00113-6](https://doi.org/10.1016/S0301-2115(02)00113-6).
- Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Ascher-Landsberg J. 2002.** Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. *BJOG* **109**:1373–1376 DOI [10.1046/j.1471-0528.2002.02194.x](https://doi.org/10.1046/j.1471-0528.2002.02194.x).
- Kusanovic JP, Espinoza J, Romero R, Hoppensteadt D, Nien JK, Kim CJ, Erez O, Soto E, Fareed J, Edwin S, Chaiwerapongsa T, Than NG, Yoon BH, Gomez R, Papp Z, Hassan SS. 2007.** Plasma protein Z concentrations in pregnant women with idiopathic intrauterine bleeding and in women with spontaneous preterm labor. *Journal of Maternal–Fetal and Neonatal Medicine* **20**:453–463 DOI [10.1080/14767050701398272](https://doi.org/10.1080/14767050701398272).
- Lanir N, Aharon A, Brenner B. 2003.** Procoagulant and anticoagulant mechanisms in human placenta. *Seminars in Thrombosis and Hemostasis* **29**:175–184 DOI [10.1055/s-2003-38833](https://doi.org/10.1055/s-2003-38833).
- Laskowski M, Kato I. 1980.** Protein inhibitors of proteinases. *Annual Review of Biochemistry* **49**:593–626 DOI [10.1146/annurev.bi.49.070180.003113](https://doi.org/10.1146/annurev.bi.49.070180.003113).
- Lockwood CJ. 2006.** Pregnancy-associated changes in the hemostatic system. *Clinical Obstetrics and Gynecology* **49**:836–843 DOI [10.1097/01.grf.0000211952.82206.16](https://doi.org/10.1097/01.grf.0000211952.82206.16).
- Lockwood CJ, Bach R, Guha A, Zhou XD, Miller WA, Nemerson Y. 1991.** Amniotic fluid contains tissue factor, a potent initiator of coagulation. *American Journal of Obstetrics and Gynecology* **165**:1335–1341 DOI [10.1016/S0002-9378\(12\)90756-5](https://doi.org/10.1016/S0002-9378(12)90756-5).
- Lockwood CJ, Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F. 2007.** The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. *Seminars in Thrombosis and Hemostasis* **33**:111–117 DOI [10.1055/s-2006-958469](https://doi.org/10.1055/s-2006-958469).
- Lockwood CJ, Krikun G, Schatz F. 1999.** The decidua regulates hemostasis in human endometrium. *Seminars in Reproductive Endocrinology* **17**:45–51 DOI [10.1055/s-2007-1016211](https://doi.org/10.1055/s-2007-1016211).

- Lockwood CJ, Krikun G, Schatz F. 2001.** Decidual cell-expressed tissue factor maintains hemostasis in human endometrium. *Annals of the New York Academy of Sciences* **943**:77–88 DOI [10.1111/j.1749-6632.2001.tb03793.x](https://doi.org/10.1111/j.1749-6632.2001.tb03793.x).
- Lockwood CJ, Toti P, Arcuri F, Paidas M, Buchwalder L, Krikun G, Schatz F. 2005.** Mechanisms of abruption-induced premature rupture of the fetal membranes: thrombin-enhanced interleukin-8 expression in term decidua. *American Journal of Pathology* **167**:1443–1449 DOI [10.1016/S0002-9440\(10\)61230-8](https://doi.org/10.1016/S0002-9440(10)61230-8).
- Mackenzie AP, Schatz F, Krikun G, Funai EF, Kadner S, Lockwood CJ. 2004.** Mechanisms of abruption-induced premature rupture of the fetal membranes: thrombin enhanced decidual matrix metalloproteinase-3 (stromelysin-1) expression. *American Journal of Obstetrics and Gynecology* **191**:1996–2001 DOI [10.1016/j.ajog.2004.08.003](https://doi.org/10.1016/j.ajog.2004.08.003).
- Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. 2001.** Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. *Thrombosis and Haemostasis* **86**:800–803.
- Mayhew TM, Ohadike C, Baker PN, Crocker IP, Mitchell C, Ong SS. 2003.** Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. *Placenta* **24**:219–226 DOI [10.1053/plac.2002.0900](https://doi.org/10.1053/plac.2002.0900).
- Midderdorp S. 2007.** Thrombophilia and pregnancy complications: cause or association? *Journal of Thrombosis and Haemostasis* **5**(Suppl 1):276–282 DOI [10.1111/j.1538-7836.2007.02501.x](https://doi.org/10.1111/j.1538-7836.2007.02501.x).
- Nath CA, Ananth CV, Smulian JC, Shen-Schwarz S, Kaminsky L. 2007.** New Jersey-placental abruption study investigators. Histologic evidence of inflammation and risk of placental abruption. *American Journal of Obstetrics and Gynecology* **197**:319.e1–319.e6 DOI [10.1016/j.ajog.2007.06.012](https://doi.org/10.1016/j.ajog.2007.06.012).
- Ndonwi M, Broze G. 2008.** Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. *Journal of Thrombosis and Haemostasis* **6**:1044–1046 DOI [10.1111/j.1538-7836.2008.02980.x](https://doi.org/10.1111/j.1538-7836.2008.02980.x).
- Nien JK, Romero R, Hoppensteadt D, Erez O, Espinoza J, Soto E, Kusanovic JP, Gotsch F, Kim CJ, Mittal P, Fareed J, Santolaya J, Chaiworapongsa T, Edwin S, Pineles B, Hassan S. 2008.** Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z. *Journal of Maternal–Fetal and Neonatal Medicine* **21**:629–637 DOI [10.1080/14767050802214659](https://doi.org/10.1080/14767050802214659).
- Obiewke BC, Chard T. 1981.** Placental protein 5: circulating levels in twin pregnancy and some observations on the analysis of biochemical data from multiple pregnancy. *European Journal of Obstetrics & Gynecology and Reproductive Biology* **12**:135–141 DOI [10.1016/0028-2243\(81\)90068-X](https://doi.org/10.1016/0028-2243(81)90068-X).
- Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, Kim CJ, Hassan SS. 2011.** Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. *Journal of Perinatal Medicine* **39**:641–652 DOI [10.1515/jpm.2011.098](https://doi.org/10.1515/jpm.2011.098).
- Omsj  IH, Oian P, Maltau JM, Osterud B. 1985.** Thromboplastin activity in amniotic fluid. *Gynecologic and Obstetric Investigation* **19**:1–5 DOI [10.1159/000299000](https://doi.org/10.1159/000299000).
-  sterud B, Bj rklid E. 2006.** Sources of tissue factor. *Seminars in Thrombosis and Hemostasis* **32**:11–23 DOI [10.1055/s-2006-933336](https://doi.org/10.1055/s-2006-933336).
- Paidas MJ, Ku DH, Lee MJ, Manish S, Thurston A, Lockwood CJ, Arkel YS. 2005.** Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. *Journal of Thrombosis and Haemostasis* **3**:497–501 DOI [10.1111/j.1538-7836.2005.01158.x](https://doi.org/10.1111/j.1538-7836.2005.01158.x).

- Preston FE, Rosendaal FR, Walker ID, Briët E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharer I, Schulman S, Van der Meer FJ. 1996. Increased fetal loss in women with heritable thrombophilia. *Lancet* 348:913–916 DOI 10.1016/S0140-6736(96)04125-6.
- Reber G, Amiral J, de Moerloose P. 1998. Modified antithrombin III levels during normal pregnancy and relationship with prothrombin fragment F1 + 2 and thrombin–antithrombin complexes. *Thrombosis Research* 91:45–47 DOI 10.1016/S0049-3848(98)00043-7.
- Redline RW, Heller D, Keating S, Kingdom J. 2005. Placental diagnostic criteria and clinical correlation—a workshop report. *Placenta* 26(Suppl A):S114–S117 DOI 10.1016/j.placenta.2005.02.009.
- Redline RW, Boyd T, Campbell V, Hyde S, Kaplan C, Khong TY, Prashner HR, Waters BL, Society for Pediatric Pathology, Perinatal Section, Maternal Vascular Perfusion Nosology Committee. 2004. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. *Pediatric and Developmental Pathology* 7(3):237–249.
- Reinthal A, Mursch-Edlmayr G, Tatra G. 1990. Thrombin–antithrombin III complex levels in normal pregnancy with hypertensive disorders and after delivery. *British Journal of Obstetrics and Gynaecology* 97:506–510 DOI 10.1111/j.1471-0528.1990.tb02520.x.
- Rerdlie RW. 2008. Placental pathology: a systematic approach with clinical correlations. *Placenta* 29(Suppl A):S86–S91 DOI 10.1016/j.placenta.2007.09.003.
- Roberts DJ, Post MD. 2008. The placenta in pre-eclampsia and intrauterine growth restriction. *Journal of Clinical Pathology* 61:1254–1260 DOI 10.1136/jcp.2008.055236.
- Rodger MA, Paidas M, McLintock C, Middeldorp S, Kahn S, Martinelli I, Hague W, Rosene Montella K, Greer I. 2008. Inherited thrombophilia and pregnancy complications revisited. *Obstetrics and Gynecology* 112:320–324 DOI 10.1097/AOG.0b013e31817e8acc.
- Romero R. 2009. Prenatal medicine: the child is the father of the man. 1996. *Journal of Maternal–Fetal and Neonatal Medicine* 22:636–639 DOI 10.1080/14767050902784171.
- Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, Chaiworapongsa T, Mazor M. 2006. The preterm parturition syndrome. *BJOG* 113(Suppl 3):17–42 DOI 10.1111/j.1471-0528.2006.01120.x.
- Romero R, Gonçalves LF, Kusanovic JP, Devesa R, Espinoza J. 2006. Mechanisms of preterm labor and preterm premature rupture of the membranes. In: Kurjak A, Chervenak F, eds. *Textbook of perinatal medicine*. 2nd Edition. Milton Park: Informa Healthcare, 1379–1393.
- Rosen T, Kuczynski E, O'Neill LM, Funai EF, Lockwood CJ. 2001. Plasma levels of thrombin–antithrombin complexes predict preterm premature rupture of the fetal membranes. *Journal of Maternal–Fetal and Neonatal Medicine* 10:297–300 DOI 10.1080/jmf.10.5.297.300.
- Rosen T, Schatz F, Kuczynski E, Lam H, Koo AB, Lockwood CJ. 2002. Thrombin-enhanced matrix metalloproteinase-1 expression: a mechanism linking placental abruption with premature rupture of the membranes. *Journal of Maternal–Fetal and Neonatal Medicine* 11:11–17 DOI 10.1080/jmf.11.1.11.17.
- Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. 1995. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. *American Journal of Obstetrics and Gynecology* 173:1049–1057 DOI 10.1016/0002-9378(95)91325-4.
- Salafia CM, Pezzullo JC, Ghidini A, Lopèz-Zeno JA, Whittington SS. 1998. Clinical correlations of patterns of placental pathology in preterm pre-eclampsia. *Placenta* 19:67–72 DOI 10.1016/S0143-4004(98)90100-X.

- Salafia CM, Vogel CA, Vintzileos AM, Bantham KE, Pezzullo J, Silberman L. 1991. Placental pathologic findings in preterm birth. *American Journal of Obstetrics and Gynecology* 165:934–938 DOI 10.1016/0002-9378(91)90443-U.
- Sarig G, Blumenfeld Z, Leiba R, Lanir N, Brenner B. 2005. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. *Thrombosis and Haemostasis* 94:980–985.
- Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisløff F. 1999. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. *ACTA Obstetrica et Gynecologica Scandinavica* 78:191–197 DOI 10.1080/j.1600-0412.1999.780304.x.
- Seppälä M, Wahlström T, Bohn H. 1979. Circulating levels and tissue localization of placental protein five (PP5) in pregnancy and trophoblastic disease: absence of PP5 expression in the malignant trophoblast. *International Journal of Cancer* 24:6–10 DOI 10.1002/ijc.2910240103.
- Sheu JR, Hsiao G, Luk HN, Chen YW, Chen TL, Lee LW, Lin CH, Chou DS. 2002. Mechanisms involved in the antiplatelet activity of midazolam in human platelets. *Anesthesiology* 96:651–658 DOI 10.1097/0000542-200203000-00022.
- Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H. 1997. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. *American Journal of Hematology* 55:169–174 DOI 10.1002/(SICI)1096-8652(199707)55:4<169::AID-AJH1>3.0.CO;2-Q.
- Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. 2006. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. *Blood* 107:3173–3180 DOI 10.1182/blood-2005-10-4111.
- Sood R, Sholl L, Isermann B, Zogg M, Coughlin SR, Weiler H. 2008. Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. *Blood* 112:585–591 DOI 10.1182/blood-2007-09-111302.
- Sørensen JD, Secher NJ, Jespersen J. 1995. Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of normal pregnancy. A possible link to placental function. *ACTA Obstetrica et Gynecologica Scandinavica* 74:257–261 DOI 10.3109/00016349509024445.
- Sprecher CA, Kisiel W, Mathewes S, Foster DC. 1994. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. *Proceedings of the National Academy of Sciences of the United States of America* 91:3353–3357 DOI 10.1073/pnas.91.8.3353.
- Stephenson CD, Lockwood CJ, Ma Y, Guller S. 2005. Thrombin-dependent regulation of matrix metalloproteinase (MMP)-9 levels in human fetal membranes. *Journal of Maternal–Fetal and Neonatal Medicine* 18:17–22 DOI 10.1080/14767050500123632.
- Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. 1984. Haemostasis in normal pregnancy. *Thrombosis and Haemostasis* 52:176–182.
- Tay SP, Cheong SK, Boo NY. 2003. Circulating tissue factor, tissue factor pathway inhibitor and D-dimer in umbilical cord blood of normal term neonates and adult plasma. *Blood Coagulation & Fibrinolysis* 14:125–129 DOI 10.1097/00001721-200302000-00002.
- Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. 1998. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 *Escherichia coli*. *Blood* 91:1609–1615.
- Teng Y, Jiang R, Lin Q, Ding C, Ye Z. 2010. The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. *Thrombosis Research* 126:e41–e45 DOI 10.1016/j.thromres.2010.02.012.

- Udagawa K, Miyagi Y, Hirahara F, Miyagi E, Nagashima Y, Minaguchi H, Misugi K, Yasumitsu H, Miyazaki K. 1998. Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by *in situ* hybridization. *Placenta* 19:217–223 DOI 10.1016/S0143-4004(98)90011-X.
- Uszyński M. 1997. Generation of thrombin in blood plasma of non-pregnant and pregnant women studied through concentration of thrombin–antithrombin III complexes. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 75:127–131 DOI 10.1016/S0301-2115(97)00101-2.
- Uszyński M, Zekanowska E, Uszyński W, Kuczyński J. 2001. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic fluid and blood plasma: implications for the mechanism of amniotic fluid embolism. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 95:163–166 DOI 10.1016/S0301-2115(00)00448-6.
- VanWijk MJ, Boer K, Berckmans RJ, Meijers JC, Van der Post JA, Sturk A, VanBavel E, Nieuwland R. 2002. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. *Thrombosis and Haemostasis* 88:415–420.
- Walker MC, Garner PR, Keely EJ, Rock GA, Reis MD. 1997. Changes in activated protein C resistance during normal pregnancy. *American Journal of Obstetrics and Gynecology* 177:162–169 DOI 10.1016/S0002-9378(97)70456-3.
- Xiong Y, Zhou Q, Jiang F, Zhou S, Lou Y, Guo Q, Liang W, Kong D, Ma D, Li X. 2010. Changes of plasma and placental tissue factor pathway inhibitor-2 in women with preeclampsia and normal pregnancy. *Thrombosis Research* 125:e317–e322 DOI 10.1016/j.thromres.2010.02.017.
- Yalinkaya A, Erdemoglu M, Akdeniz N, Kale A, Kale E. 2006. The relationship between thrombophilic mutations and preeclampsia: a prospective case-control study. *Annals of Saudi Medicine* 26:105–109.
- Yin ZF, Huang ZF, Cui J, Fiehler R, Lasky N, Ginsburg D, Broze Jr GJ. 2000. Prothrombotic phenotype of protein Z deficiency. *Proceedings of the National Academy of Sciences of the United States of America* 97:6734–6738 DOI 10.1073/pnas.120081897.
- Yoneyama Y, Suzuki S, Sawa R, Otsubo Y, Power GG, Araki T. 2000. Plasma adenosine levels increase in women with normal pregnancies. *American Journal of Obstetrics and Gynecology* 182:1200–1203 DOI 10.1067/mob.2000.104832.
- Yuen PM, Yin JA, Lao TT. 1989. Fibrinopeptide A levels in maternal and newborn plasma. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 30:239–244 DOI 10.1016/0028-2243(89)90007-5.